A prolonged antibiotic protocol to treat persistent Chlamydophila pneumoniae infection improves the extracranial venous circulation in multiple sclerosis

Abstract

Objective

Chronic cerebrospinal venous insufficiency (CCSVI) is a condition associated with multiple sclerosis (MS). One mechanism that has been proposed is that the venous obstructions found in MS are due to a chronic persistent venulitis caused by the intra-cellular bacterial parasite, Chlamydophila pneumoniae (Cpn). The objective of the current study is to determine the effect of a combined antibiotic protocol (CAP) on the venous flow in MS patients as measured by a quantitative duplex ultrasound examination (QDUS).

Method

A non-randomised before-after cohort study was conducted to investigate differences in blood flow volumes pre and 6-months post antibiotic treatment for Cpn infection. Flow volume data were measured by QDUS across affected and unaffected sides from multiple veins segments, including internal jugular vein (IJV) segments J2 and J3, and vertebral vein (VV), as well as global arterial blood flow (GABF).

Results

91 patients were included in the study. 64 (70%) were found to have positive Cpn serology. There was a statistically significant post-treatment difference seen for the affected side of Cpn infected patients (mean difference = 56 mL/min, p = 0.02). There was a non-significant increase seen for the affected side of uninfected patients (mean difference = 23 mL/min, p = 0.2). The difference in these effects (34 mL/min) was not statistically significant (p = 0.3). The mean flow rate decreased in the unaffected side for both infected (−27 mL/min, p = 0.5) and uninfected patients (−69 mL/min, p = 0.01).

There was a statistically significant post-treatment increase in GABF for the infected patients (mean difference = 90 mL/min, p = 0.02) and a difference of 76 mL/min for non-infected patients (p = 0.01).

Conclusion

A CAP appears to improve the extra-cranial circulation in patients diagnosed with MS. This effect is statistically significant in patients with positive Cpn serology, although patients with negative Cpn serology also show some benefit, betraying a lack of specificity of this effect.

Keywords

Antibiotic protocol multiple sclerosis duplex ultrasound venous

Get full access to this article

View all access options for this article.

References

Stratton

Wheldon

. Multiple sclerosis: An infectious syndrome involving Chlamydophila pneumoniae. Trends Microbiol 2006; 14: 474–479.

Koskiniemi

Gencay

Salonen

. Chlamydia pneumoniae associated with central nervous system infections. Eur J Neurol 1996; 36: 160–163.

Sriram

Stratten

Yao

S-y

et al.

Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6–14.

Lay-Schmitt

Bendl

Hildt

et al.

Evidence for infection with Chlamydia pneumoniae in a sub-group of patients with multiple sclerosis. Ann Neurol 2000; 47: 602–604.

Sotgiu

Piana

Pugliatti et al.

Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls. Mult Scler 2001; 7: 371–374.

Hao

Miyashita

Matsui

et al.

Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis. Mult Scler 2002; 8: 436–440.

Grimaldi

LME

Pincherle

Martinelli-Boneschi

et al.

An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Mult Scler 2003; 9: 467–467.

Rostasy

Reiber

Pohl

et al.

Chlamydia pneumoniae in children with MS: Frequency and quantity of intrathecal antibodies. Neurology 2003; 61: 125–128.

Dong-Si

Weber

Liu

et al.

Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. J Neurol 2004; 251: 542–547.

10.

Contini

Cultrera

Seraceni

et al.

Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 360–369.

11.

Sriram

Ljunggren-Rose

Yao

S-Y

et al.

Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. J Infect Dis 2005; 192: 1219–1228.

12.

Contini

Seraceni

Castellazzi

et al.

Chlamydophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. Neurosci Res 2008; 62: 58–61.

13.

Pohl

Rostasy

Maass

et al.

Recurrent optic neuritis associated with Chlamydia pneumoniae infection of the central nervous system. Dev Med Child Neuro 2006; 48: 770–772.

14.

Sriram

Yao

S-y

Stratton

et al.

Comparative study of the presence of Chlamydia pneumonia in cerebrospinal fluid of patients with clinically definite and monosymptomatic multiple sclerosis. Clin Diag Lab Immun 2002; 9: 1332–1337.

15.

Parrat

Tavendale

O’Riordan

et al.

Chlamydia pneumoniae specific serum immune complexes in patients with multiple sclerosis. Mult Scler 2007; 14: 292–299.

16.

Thibault

. Multiple sclerosis: A chronic infective cerebrospinal venulitis? Phlebology 2012; 27: 207–218.

17.

Contini

Seraceni

Cultrera

et al.

Chlamydophila pneumoniae infection and its role in neurological disorders. Interdiscip Perspect Infect Dis 2010; 2010: 273573–273573. DOI: 10.1155/2010/273573.

18.

Gieffers

Rupp

Gebert

et al.

First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydophila pneumoniae. Antimicrob Agents Chemother 2004; 48: 1402–1405.

19.

Stratton

Wheldon

. Antimicrobial treatment of multiple sclerosis. Infection 2007; 35: 383–385.

20.

Gieffers

Fullgraf

Jahn

et al.

Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 51–56.

21.

Mitchell WM and Stratton CW. Diagnosis and management of infection caused by Chlamydia. United States Patent. US 6,884,784, 2005.

22.

Villareal

Whittum-Hudson

Hudson

. Persistent Chlamydiae and chronic arthritis. Arthritis Res 2002; 4: 5–9.

23.

Zamboni

Galeotti

Menegatti

et al.

Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 392–399.

24.

Zwischenberger

Beasley

Davenport

et al.

Meta-analysis of the correlation between chronic cerebrospinal venous insufficiency and multiple sclerosis. Vasc Endovasc Surg 2013; 47: 620–624.

25.

Costello

Modi

Lautner

et al.

Validity of the diagnostic criteria for chronic cerebro-spinal venous insufficiency and association with multiple sclerosis. CMAJ 2014; 186: 418–426.

26.

Chambers

Cameron

et al.

Chronic cerebrospinal venous insufficiency is not more prevalent in patients with mild multiple sclerosis – a sonographer blinded case-control ultrasound study. Mult Scler 2013; 19: 749–756.

27.

Thibault

Lewis

Niblett

. Objective duplex ultrasound examination of the extracranial circulation in patients undergoing venoplasty of internal jugular vein stenosis: A pilot study. Phlebology 2015; 30: 98–104.

28.

Chambers

Churilov

et al.

Internal jugular and vertebral vein volume flow in patients with clinically isolated syndrome or mild multiple sclerosis and healthy controls: Results from a prospective sonographer-blinded study. Phlebology 2014; 29: 528–535.

29.

Zamboni

. Why current Doppler ultrasound methodology is inaccurate in assessing cerebral venous return: The alternative of the ultrasonic jugular venous pulse. Behav Neurol 2016; 2016: 7082856–7082856. DOI: 10.1155/2016/7082856.

30.

Valdueza

von Münster

Hoffman

et al.

Postural dependency of the cerebral venous outflow. Lancet 2000; 355: 200–201.

31.

Putnam

Adler

. Vascular architecture of the lesions of multiple sclerosis. Arch Neurol Psychiat 1937; 38: 1–15.

32.

Adams

Poston

Buk

et al.

Inflammatory vasculitis in multiple sclerosis. J Neurol Sci 1985; 69: 269–283.

33.

Zamboni

Galeotti

. The chronic cerebrospinal venous insufficiency syndrome. Phlebology 2010; 25: 269–279.

34.

Lee

Laredo

Neville

. Embryological background of truncular venous malformation in the extracranial venous pathways as the cause of chronic cerebrospinal venous insufficiency. In Angiol 2010; 29: 95–108.

35.

Kurtzke

. Multiple sclerosis in time and space – geographical clues to cause. J Neurovirol 2000; 6: 134–140.

36.

Zamboni

Tisato

Menegatti

et al.

Ultrastructure of internal jugular vein defective valves. Phlebology 2015; 30: 644–647.

37.

Kurtzke

. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6: 382–427.

38.

Cole

Witte

. Lymph Culture: A new tool for the investigation of human infections. Ann Surg 1969; 170: 705–713.

39.

Nathanson

Savitsky

. Platelet adhesive index studies in multiple sclerosis and other neurologic disorders. Bull NY Acad Med 1952; 28: 462–468.

40.

Millar

Merrett

Dalby

. Platelet stickiness in multiple sclerosis. J Neurol Neurosurg Psychiatry 1966; 29: 187–189.

41.

Bolton

Hampton

Phillipson

. Platelet behaviour and plasma phospholipids in multiple sclerosis. Lancet 1968; 1: 99–104.

42.

Andreoli

Cazzullo

. Platelet behaviour in multiple sclerosis. Lancet 1968; 1: 528–529.

43.

Sheremata

Horstman

et al.

Evidence of platelet activation in multiple sclerosis. J Neuroinflamm 2008; 5: 27–27.

44.

Kälvegren

Majeed

Bengtsson

. Chlamydia pneumoniae binds to platelets and triggers P-Selectin expression and aggregation: A causal role in cardiovascular disease? Arterioscler Thromb Vasc Biol 2003; 23: 1677–1683.

45.

Morel A, Rywaniak J, Bijak M, et al. Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients. Mol Cell Biochem. DOI: 10.1007/s11010-017-2955-7.

46.

Saikku

. Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J 1999; 138: S500–503.

47.

Lindholt

Shi

. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453–463.